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ABSTRACT: Two peptides from soybean β-conglycinin, i.e., YVVNPDNDEN (peptide 2) and YVVNPDNNEN (peptide 3),
are known to be absorbed by human enterocytes. The former is a fragment of LRVPAGTTFYVVNPDNDENLRMIA (peptide
1), previously shown to increase the low-density lipoprotein (LDL) uptake and degradation in hepatocytes. Research carried out
in silico on their interactions with the catalytic site of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCoAR) demonstrated
that they behave as competitive inhibitors of HMGCoAR activity with a statin-like mechanism, conﬁrmed by direct inhibition
experiments. Research in HepG2 cells aimed at investigating the eﬀects of these peptides on cholesterol metabolism showed that
compared to mock treatment peptide 2 at 350 μM up-regulates the mature SREBP2 protein level by 134.0 ± 10.5%, increases the
LDLR protein level by 152.0 ± 20.0%, and enhances the HMGCoAR protein production by 171 ± 29.9%, whereas peptide 3 up-
regulates the mature SREBP2 protein level by 158.0 ± 9.2%, increases the LDL level 164.0 ± 17.9%, and induces a HMGCoAR
protein increase by 170 ± 50.0%.
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■ INTRODUCTION
The hypocholesterolemic activity of soy foods has been known
for many years.1−3 Studies in animals4 and in humans5,6 have
demonstrated that the mechanism of action is linked to the up-
regulation of low-density lipoprotein receptors (LDLR), which
are relevant in the metabolic degradation of low-density
lipoproteins (LDL). Other studies7 have shown that the
protein is a main bioactive soybean component. The two major
components of soybean protein are glycinin, a nonglycosylated
11S globulin (legumin), and β-conglycinin, a glycosylated 7S
globulin (vicilin).8 The latter consists of diﬀerent combinations
of three major subunits, namely, α, α′, and β. Experimental
evidence in animals9−11 indicates that the α′ subunit has a
major role in the cholesterol-lowering properties of soybean.
Because proteins are digested in the gastroenteric system,
their activities should depend on the release of bioactive
peptides encrypted in their sequences.12−18 Lovati and co-
workers7 have suggested that speciﬁc peptides from β-
conglycinin are important for the observed hypocholester-
olemic activity. In particular, they tested LRVPAGTTFYVV-
NPDNDENLRMIA (peptide 1), corresponding to positions
301−324 of the α′ subunit of β-conglycinin (UNIProtKB:
P11827), at a concentration of 10−4 mol/L cells and
demonstrated that it increases 125I-LDL uptake in human
HepG2 cells by 41% and its degradation by 10% versus the
vehicle. Independently, we have recently demonstrated19 that
IAVPGEVA, IAVPTGVA, and LPYP (three peptides from soy
glycinin) modulate the cholesterol metabolism in HepG2 cells
through activation of the low-density lipoprotein receptor
(LDLR) sterol regulatory-element-binding protein 2 (SREBP2)
and inhibition of 3-hydroxy-3-methylglutaryl CoA reductase
(HMGCoAR).20 HMGCoAR is a key enzyme in the synthesis
of endogenous cholesterol and the main target of statins, which
interact with this enzyme as competitive inhibitors.21
Although in principle bioactive peptides might exert their
action locally in the gastrointestinal tract, intestinal absorption
prior to distribution to peripheral organs is certainly a main key
factor aﬀecting bioavailability, kinetics, and systemic actions of
food peptides in vivo.16 Interestingly, a very recent study,22
based on a phytochemomic approach, has investigated the in
vitro digestion of β-conglycinin and the potential uptake of the
generated peptides by human intestinal CaCo-2 cell layers.
YVVNPDNDEN (peptide 2) and YVVNPDNNEN (peptide 3)
were among the 22 peptides transferred from the apical to the
basolateral compartment in these experiments.22 The former
corresponds to positions 310−319 of the α′ subunit of β-
conglycinin (UNIProtKB: P11827) and is a fragment of the
above cited peptide 1 (LRVPAGTTFYVVNPDNDEN-
LRMIA);7 the latter is structurally very similar to peptide 1
and corresponds instead to positions 232−241 of the α subunit
of β-conglycinin (UNIProtKB: P13916).
The fact that peptides 2 and 3 are bioavailable in Caco-2 cells
has prompted us to investigate their interactions with the
catalytic site of HMGCoAR by using molecular modeling tools
and to characterize the molecular mechanism through which
they potentially mediate a hypocholesterolemic eﬀect in HepG2
cells by using a combination of molecular techniques. Finally,
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again by molecular modeling, we investigated for comparison
the interaction of peptide 1 with the catalytic site of
HMGCoAR.
■ MATERIALS AND METHODS
Chemicals. Dulbecco’s modiﬁed Eagle’s medium (DMEM), L-
glutamine, fetal bovine serum (FBS), phosphate-buﬀered saline (PBS),
penicillin/streptomycin, chemiluminescent reagent, and 96-well plates
were purchased from Euroclone (Milan, Italy). Bovine serum albumin
(BSA), RIPA buﬀer, HMGCoAR assay kit, lovastatin, and the antibody
against β-actin were bought from Sigma-Aldrich (St. Louis, MO,
USA). The antibody against HMGCoAR was bought from Abcam
(Cambridge, UK). The antibodies against SREBP-2, rabbit Ig-HRP,
mouse Ig-HRP, phenylmethanesulfonylﬂuoride (PMSF), Na-orthova-
nadate inhibitors, and goat anti-rabbit Ig-HRP were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The
antibodies against LDLR were bought from Pierce (Rockford, IL,
USA); the inhibitor cocktail Complete Midi was purchased from
Roche (Basel, Swiss). Mini protean TGX precast gel 7.5% and Mini
nitrocellulose Transfer Packs were purchased from BioRad (Hercules,
CA, USA). YVVNPDNDEN and YVVNPDNNEN were bought from
PRIMM (Milan, Italy), which certiﬁed >95% purity by HPLC.
Computational Methods. The structures of peptides 1−3 were
built by using two diﬀerent strategies. The shortest derivatives
(peptides 2 and 3) were manually modeled in a canonical α-helix by
using the Peptide Builder function of the VEGA suite of programs;
then, their conformational proﬁles were explored by a MonteCarlo
procedure, which produced 20 000 conformers by randomly rotating
the backbone torsions only. The ﬁnal geometries were then clustered
according to their similarity to discard redundant ones; here, two
conformations were considered as nonredundant when they diﬀered
by more than 60° in at least one backbone torsion angle. For each
cluster, the lowest energy structure was collected and memorized. By
contrast, the structure of the longest peptide (1) was generated by
homology modeling, using the Fugue online program, on the basis of
the resolved structure of phaseolin as the template (Protein Database
(PDB) ID: 2PHL). This model was completed by adding side chains
and hydrogen atoms and then minimized by keeping the backbone
atoms ﬁxed to preserve the predicted folding.
Among the resolved human HMG-CoA reductase structures, the
study involved the complex between the enzyme and a statin (i.e.,
(3R,5R)-7-[2-(4-ﬂuorophenyl)-4-{[(1S)-2-hydroxy-1-phenylethyl]-
carbamoyl}-5-(1-methylethyl)-1H-imidazol-1-yl]-3,5-dihydroxyhepta-
noic acid, PDB ID: 3CCZ) because this showed the best resolution
(1.70 Å).21 Even though the resolved structure is a homotetramer, the
simulations were focused on a functionally active homodimer, which
completely encompasses the catalytic binding site. After deleting water
molecules, ions, and crystallization additives, the selected dimer bound
to the statin was completed by adding the hydrogen atoms and then
optimized by keeping the backbone atoms ﬁxed to preserve the
resolved folding. The inhibitor was ﬁnally deleted, and the obtained
protein structure underwent the following docking simulations.
Although requiring diﬀerent strategies, all docking simulations were
carried out by using the program Protein−Ligand ANT System
(PLANTS, release 1.1),23 which generates reliable ligand poses by
using ant colony optimization algorithms (ACO).
For the shortest peptides (peptides 2 and 3), docking simulations
involved the 20 lowest energy conformations as derived by the
previous MonteCarlo analysis in order to minimize the biasing eﬀects
of the starting conformation on the obtained results. In detail, the
search was focused on a 15.0 Å radius sphere around the bound statin,
thus including the entire binding cavity. PLANTS was used with
default settings and without geometric constraints: Speed 1 was used,
and 5 poses were generated and scored for each conformer by using
the ChemPLP function. The obtained poses were evaluated by
considering both the docking scores and the conformational energies
of the docked conformers. The best poses were then minimized,
keeping ﬁxed all atoms inside a 15.0 Å radius sphere around the bound
peptide. Although adopting the same computational procedures
already described, the docking study for the longest peptide 1 was
focused on the single conformation as derived by homology modeling.
The computed complexes for peptide 1 and 2 underwent 10 ns
molecular dynamic (MD) study. It should be noted here that the MD
simulations had the primary objective of assessing the stability of the
generated complexes as well as of their key stabilizing contacts and
were not aimed at investigating the conformational changes induced
by the bound ligand on the protein structure because this would have
clearly required longer simulations. First, the complexes were
embedded in a cubic box of water (85 Å × 85 Å × 85 Å) containing
16 250 solvent molecules. The systems were then minimized to
optimize the relative position of the solvent molecules and then were
subjected to MD runs with the following characteristics: (a) Periodic
boundary conditions (95 Å × 95 Å × 95 Å) were applied to stabilize
the simulation space. (b) Newton’s equation was integrated using the
r-RESPA method (every 4 fs for long-range electrostatic forces, 2 fs for
short-range non bonded forces, and 1 fs for bonded forces). (c) The
long-range electrostatic potential was computed by the Particle Mesh
Ewald summation method (80 × 80 × 80 grid points). (d) The
temperature was maintained at 300 ± 10 K by Langevin’s algorithm.
(e) Lennard-Jones (L-J) interactions were calculated with a cutoﬀ of
10 Å, and the pair list was updated every 20 iterations. (f) A frame was
memorized every 10 ps, thus generating 1000 frames. (g) No
constraints were imposed on the systems. The simulations were
carried out in two phases: an initial period of heating from 0 to 300 K
over 300 000 iterations (300 ps, i.e., 1 K/ps) and the monitored phase
of 10 ns. The mentioned minimizations were carried out using the
conjugate gradient algorithm until the rms gradient was smaller than
0.01 kcal mol−1 Å−1. All calculations were carried out by Namd2.10,24
with the force-ﬁeld CHARMm v22 and Gasteiger’s atomic charges.
HMGCoAR Activity Assay. HMGCoAR (catalytic domain),
NADPH, assay buﬀer, and substrate solution were provided in the
HMGCoAR assay kit (Sigma-Aldrich, St. Louis, MO, USA). The
experiments were carried out at 37 °C following the manufacturer’s
instructions. In particular, each reaction (200 μL) was prepared by
adding the reagents in the following order: 1X assay buﬀer; peptide 2
(at 100, 125, 150, and 250 μM), and peptide 3 (at 150, 175, 200, and
250 μM), or vehicle (C); NADPH (4 μL); substrate solution (12 μL);
and ﬁnally HMGCoAR (2 μL). Subsequently, the samples were mixed,
and the absorbance at 340 nm was read by a microplate reader
(Synergy H1 from Biotek, Bad Friedrichshall, Germany) at 0 and 10
min. The HMGCoA-dependent oxidation of NADPH and the
inhibition properties of soy peptides were measured by the absorbance
reduction, which is directly proportional to enzyme activity.
Cell Line Culture. The HepG2 cell line was bought from ATCC
(HB-8065, ATCC from LGC Standards, Milan, Italy). It was cultured
in high-glucose DMEM with stable L-glutamine supplemented with
10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin
(complete growth medium) and incubated at 37 °C under 5% CO2
atmosphere. HepG2 cells were used for no more than 20 passages after
thawing because the increase of passage number may change cell
characteristics and impair assay results.
Western Blot Analysis. HepG2 (1.5 × 105 cells/well of a 24-well
plate) were treated with peptides 2 and 3 (each 350 and 500 μM) for
24 h. After each treatment, cells were scraped in 40 μL of ice-cold lysis
buﬀer (RIPA buﬀer + inhibitor cocktail + 1:100 PMSF + 1:100 Na-
orthovanadate) and transferred in an ice-cold microcentrifuge tube.
After centrifugation at 16 060 g for 15 min at 4 °C, the supernatant
was recovered and transferred to a new ice-cold tube. Total proteins
were quantiﬁed by the Bradford method, and 50 μg of total proteins
were loaded on a precast 7.5% sodium dodecyl sulfate−polyacrylamide
(SDS-PAGE) gel at 130 V for 45 min. Subsequently, the gel was pre-
equilibrated with 0.04% SDS in H2O for 15 min at room temperature
(RT) and transferred to a nitrocellulose membrane (Mini nitro-
cellulose Transfer Packs), using a Trans-blot Turbo at 1.3 A and 25 V
for 7 min. Target proteins on the milk-blocked membrane were
detected by primary antibodies as follows: rabbit anti-SREBP2, anti-
LDLR, anti-HMGCoAR, and anti-β-actin. Secondary antibodies
conjugated with HRP and a chemiluminescent reagent were used to
visualize target proteins, and their signal was quantiﬁed using the
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ImageJ Software. The internal control β-actin was used to normalize
loading variations.
Fluorescent LDL Uptake Cell-Based Assay. A total of 3 × 104
HepG2 cells were seeded per well of 96-well plates and kept in
complete growth medium for 2 days before treatment. On the third
day, cells were treated with peptide 2 and 3 at the concentrations of 50
and 100 μM, respectively, or mock treatment (H2O) for 24 h. At the
end of the treatment period, the culture medium was replaced with 50
μL/well LDL-DyLight 550 working solution (Cayman Chemical
Company, Ann Arbor, Michigan, USA). The cells were additionally
incubated for 2 h at 37 °C; then, the culture medium was aspirated,
washed, and replaced with PBS (100 μL/well). The degree of LDL
uptake was measured using the Synergy H1 ﬂuorescent plate reader
from Biotek (excitation and emission wavelengths 540 and 570 nm,
respectively).
Statistical Analysis. Statistical analyses were carried out by one-
way ANOVA (Graphpad Prism 6) followed by Dunnett’s test and/or t
test. Values were expressed as means ± SEM; P values < 0.05 were
considered to be signiﬁcant.
■ RESULTS
Molecular Modeling Investigation. An in silico modeling
study was undertaken to investigate the potential interaction of
peptides 1−3 with the catalytic domain of HMGCoAR. Figure
1 shows a bidimensional scheme summarizing the key
interactions stabilizing the putative complex between peptide
2 and the enzymatic cavity of HMGCoAR, whereas Figure S1A
gives an overall view of the pose of peptide 2 within the
HMGCoAR displayed by cartoon. Notably, most key polar
interactions are elicited by the last ﬁve residues of the C
terminus, whereas the ﬁrst N-terminal residues are mostly
involved in hydrophobic contact, with the exception of the N-
terminal ammonium head, which is engaged in ionic
interactions with Glu559 and Asp767, and the phenolic
function of Tyr1, which stabilizes H bonds with Thr557 and
Thr758. In detail, Asp6, Asp8, and Glu9 are engaged in an
extended network of ion pairs involving the rich set of
positively charged residues, which characterize the catalytic
pocket of HMGCoAR and surround the C-terminal portion of
the bound peptide, whereas the carboxyl terminus and Asn6
elicit only H bonds.
Figure 1 highlights (underlined) the residues stabilizing the
key contacts with the peptide 2 that were also found to be
involved in the stabilization of the experimentally resolved
complex between HMGCoAR and a statin. Notably, the
underlined residues mostly interact with the negatively charged
C-terminal portion of peptide 2, thus conﬁrming that this
segment is primarily involved in the inhibition of HMGCoAR
by mimicking most of the polar interactions already seen for the
binding of the statin polar moieties. In contrast, the
hydrophobic N-terminal portion is inserted in a deeper and
rather apolar subpocket that does not match that accommodat-
ing the statin hydrophobic moieties but rather roughly
corresponds to that harboring the NADPH cofactor. Indeed,
the statin polar groups interact with the residues contacting the
HMG groups, whereas the statin apolar moieties are
accommodated in the apolar subpocket interacting with the
pantothenic acid moiety of CoA, and no region of the
NADP(H) binding site is engaged by statins. Here, a diﬀerent
arrangement is observed because the hydrophobic portion of
peptide 2 is partly accommodated in the elongated binding
cavity of the cofactor, thus suggesting that it may also aﬀect the
NADPH binding. Similar docking simulations of peptide 3
revealed that the mutation Asp8 into Asn8 does not markedly
aﬀect the interaction pattern because Asn8 elicits H bonds with
Lys662 (already seen for peptide 2) and Glu665 (complex not
shown).
Figure S1B shows the pose of peptide 1 and suggests the β-
hairpin motif stabilized by several intramolecular polar contacts,
among which the salt bridge between the two ionized termini
has a key role in determining such a folded structure. Figure
S1B also reveals that this longer peptide is accommodated
within a more superﬁcial region of the binding cavity compared
to peptide 2, and its inhibition can be due to a sort of lid
mechanism involving additional regions adjacent to the rim of
the catalytic pocket.
Figure S2 is a schematic representation of the key contacts
stabilizing the putative complex as computed for the longer
peptide 1. Similar to what was seen for the shorter derivative,
Figure S2 reveals that the conserved portion between Asp15
and Asn19 is involved in the key polar interactions with the
ionizable residues lining the HMGCoAR binding cavity. Apart
from Arg21, which stabilizes two ion pairs with Glu559 and
Asp767, the remaining residues are generally engaged in an
extended network of intramolecular and intermolecular hydro-
phobic contacts that contribute to the overall stabilization of
the obtained complex. Remarkably, there are some residues
(highlighted in green), especially in the N-terminal region, that
are exclusively involved in intramolecular contacts. One may
imagine that such intramolecular interactions can play a dual
role because they stabilize the folded conformation and shield
some unﬁt side chains, thus minimizing potential repulsing
Figure 1. Bidimensional scheme reporting the key interactions stabilizing the putative complex for peptide 2. The residues involved in the binding of
the statin as found in the resolved crystal structure utilized here (PDB ID: 3CCZ) are underlined.
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contacts with surrounding enzyme residues (as in the case of
Arg2).
A primary objective of the MD simulations thus carried out
was to assess the stability of the computed complexes. Hence,
Figure 2 compares the rmsd values of the two bound peptides
as computed during the MD runs considering only the
backbone atoms. It reveals two markedly diﬀerent proﬁles
because peptide 2 shows a low and rather constant proﬁle,
which is suggestive of a very stable complex in which most
residues are tightly involved in key contacts. Figure S3A reports
the rmsd values as dissected per residue and computed
considering all atoms and conﬁrms the key role of the ionized
residues, which indeed remains nearly ﬁxed during all the MD
run.
In contrast, peptide 1 shows a higher and more variable
proﬁle, which may suggest that not all residues are equally
involved in the key contacts and that some portions of peptide
1 conserve a notable mobility even within the HMGCoAR
binding cavity. To better investigate this ﬁnding, Figure S3B
shows the rmsd values as dissected per residue and reveals a
signiﬁcant variability between the thus-computed rmsd values
in line with the number of polar contacts elicited by each
residue. In detail, Figure S3 conﬁrms that the region between
Asn13 and Arg21 plays a key role in complex stabilization and
indeed remains stably bound to the enzyme, whereas the
segment between Ala5 and Val12 is engaged at most in apolar
contacts and is arranged in a more superﬁcial region of the
HMGCoAR binding cavity, thus conserving a marked mobility
during the MD simulation. The two terminal segments show an
intermediate ﬂexibility probably due to the ionic contact
between the two terminal ionized groups. Overall, these results
suggest that the computed pose of peptide 1 is stable even
though a such an extended peptide cannot be completely
stabilized within the enzyme catalytic site, thus explaining the
observed residual ﬂexibility.
The satisfactory stability of the two simulated complexes is
further conﬁrmed by the dynamic proﬁle of some representa-
tive contacts as derived from MD runs and compiled in Table 1.
Indeed, the reported distance values emphasize that most key
ionic contacts are completely stable because the corresponding
distances are comprised in very narrow ranges.
Peptides 2 and 3 Inhibit the HMGCoAR in Vitro. The
experimental characterization of the molecular mechanism
through which peptides 2 and 3 may potentially mediate a
hypocholesterolemic eﬀect was carried out in two steps: ﬁrst,
evaluating their capacity to inhibit the catalytic activity of
HMGCoAR; second, investigating in HepG2 cells how they
modulate cholesterol metabolism and modify the LDL uptake.
To conﬁrm that indeed peptides 2 and 3 inhibit the catalytic
activity of HMGCoAR as their main molecular target, an in
vitro assay was carried out using the puriﬁed catalytic domain of
this enzyme. A concentration range from 100 and 250 μM was
tested. Each peptide inhibited HMGCoAR activity in a dose-
dependent manner, with an IC50 of about 150 and 200 μM for
peptides 2 and 3, respectively (Figure 3). On the basis of these
results, we decided to treat HepG2 cells in the following
experiments at slightly higher concentrations, i.e., 350 and 500
μM.
Peptides 2 and 3 Induce the LDLR-SREBP2 Pathway.
To verify the consequences of the HMGCoAR inhibition
activity exerted by peptides 2 and 3 on the modulation of the
LDLR-SREBP2 pathway, HepG2 cells were treated with both
peptides at the concentrations of 350 and 500 μM, and each
sample was investigated with immunoblotting experiments.
Figure 4A−D shows that the treatment with each peptide
induced an up-regulation of the N-terminal fragment of the
SREBP2 protein level (mature form with a molecular weight of
68 kDa). In particular, peptide 2 up-regulated the mature
SREBP2 protein level by 134.0 ± 10.5 and 141.1 ± 18.0% at
350 and 500 μM, respectively, whereas peptide 3 up-regulated
the mature SREBP2 protein level by 158.0 ± 9.2 and by 155.2
± 14.6% at 350 and 500 μM, respectively, versus the untreated
sample.
In the same experiments, the LDLR and HMGCoAR protein
level variations were also measured by immunoblotting (Figure
4B,C). All peptides increased the LDLR and HMGCoAR
protein levels, in agreement with their capacity to up-regulate
the transcriptional active SREBP2 fragment (mature-SREBP2)
protein level. In particular, peptide 2 increased the LDLR
protein level by 152.0 ± 20.0 and 167.0 ± 31.7% and peptide 3
by 164.0 ± 17.9 and 182.2 ± 41.8% versus the untreated
sample at 350 and 500 μM, respectively (Figure 4E). Peptide 2
enhanced the production of the HMGCoAR protein by 171 ±
29.9 and by 187 ± 34.6% versus the untreated sample at 350
and 500 μM, respectively, whereas peptide 3 induced an
Figure 2. Rmsd proﬁles for the simulated peptides bound to the
enzyme as derived by MD runs considering the backbone atoms only
(solid black line = peptide 1, dashed black line = peptide 2).
Table 1. Dynamic proﬁle of some representative contacts as
derived from MD runs for the two simulated complexesa
interaction distance mean
distance
minimum
distance
maximum
Peptide 2
NH3
+ → E559 2.94 ± 0.095 2.69 3.45
NH3
+ → D767 2.89 ± 0.11 2.61 3.31
Tyr1 → T557 7.84 ± 2.97 2.99 13.76
Asp6 → R590 5.04 ± 0.59 3.49 6.55
Asp6 → K692 3.08 ± 0.29 2.63 4.16
Asp6 → K735 3.04 ± 0.13 2.71 3.71
Asp8 → K662 3.16 ± 0.33 2.62 4.05
Peptide 1
Asp17 → R568 3.74 ± 0.14 3.37 4.31
Glu18 → R590 4.19 ± 0.26 3.42 4.89
Asn19 → R590 4.75 ± 1.29 2.67 8.06
Arg21 → E559 3.96 ± 0.14 3.53 4.59
Arg21 → D767 6.52 ± 0.49 4.69 7.77
aAll distances are expressed in angstroms.
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increase of the HMGCoAR protein by 170 ± 50.0 and by 177.0
± 40.5% versus the untreated sample at 350 and 500 μM,
respectively (Figure 4F).
Peptides 2 and 3 Increase HepG2 Ability to Uptake
Extracellular LDL. Fluorescent LDL uptake experiments
permitted us to evaluate the change of the functional capability
of HepG2 cells to uptake extracellular LDL after treatment with
these peptides. As shown in Figure 5, each peptide is able to
increase the LDL uptake versus the untreated sample in a
statistically signiﬁcant way. In fact, the treatments with peptide
2 and 3, at concentrations of 50 and 100 μM, led to an increase
of the LDL uptake by 64 ± 29.9 and 70 ± 14.4% and 100 ±
53.1 and 215 ± 88.1%, respectively, versus the untreated
sample.
■ DISCUSSION
Recently, our research group is dedicating much eﬀort to
investigate the potential bioactivity of plant food peptides13,17,25
because this is a very promising area in functional foods.26−28 In
the framework of research aimed at investigating and
characterizing the hypocholesterolemic eﬀects of soy peptides,
we have recently studied the mechanism of action through
which three peptides from soy glycinin exert their hypocholes-
terolemic eﬀects in HepG2 cells.19 Unfortunately, the relevant
Figure 3. Eﬀects of peptides 2 and 3 on the catalytic domain of
HMGCoAR. Bars indicate the eﬀects on the HMGCoAR activity of
(A) peptide 2 (100, 125, 150, and 250 μM) and (B) peptide 3 (150,
175, 200, and 250 μM). The HMGCoAR physiologically catalyzes the
four-electron reduction of HMGCoA to coenzyme A (CoA) and
mevalonate (HMGCoA + 2NADPH + 2H+ → mevalonate +2NADP+
+ CoA-SH). In this assay, the absorbance decrease at 340 nm, which
represents the oxidation of NADPH by the catalytic subunit of
HMGCoAR in the presence of the substrate HMGCoA, was measured
spectrophotometrically. The data points represent the averages ± SEM
of three independent experiments in triplicate. *, P < 0.05, and ***, P
< 0.0001 vs C. C = untreated samples.
Figure 4. Eﬀects of peptides 2 and 3 on the SREBP2, LDLR, and HMGCoAR protein levels. HepG2 cells (1.5 × 105) were treated with 350 and 500
μM of each peptide for 24 h, respectively. (A−C) SREBP2, LDLR, HMGCoAR, and β-actin immunoblotting signals were detected using speciﬁc
anti-SREBP2, anti-LDLR, anti-HMGCoAR, and anti-β-actin primary antibodies, respectively. (D) SREBP2, (E) LDLR, and (F) HMGCoAR signals
were quantiﬁed by ChemiDoc Image Lab (Biorad) and normalized with β-actin signals. Bars represent the averages of duplicate samples ± SEM of
three independent experiments. *, P < 0.05, **, P < 0.001, and ***, P < 0.0001 vs C. C = mock treatments.
Figure 5. LDL uptake after peptide 2 and 3 treatments. HepG2 cells
(3 × 104) were treated with 50 and 100 μM of each peptide for 24 h.
LDL-Dylight 549 (10.0 μg/mL) was then incubated for additional 2 h.
Excess of LDL-Dylight 549 was removed, cells washed twice with PBS,
and speciﬁc ﬂuorescent LDL-uptake analyzed by Synergy H1 (Biotek).
The data points represent the averages ± SEM of three independent
experiments in triplicate. **, P < 0.001, and ***, P < 0.0001, vs C. C =
untreated sample.
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issue of the actual absorbability and bioavailability of those
peptides in the gut remained unsolved.16 The present research
represents a main progress in respect to that paper because
peptides 2 and 3 are very likely to be bioavailable.22
Another important aspect of this work is that it provides new
information on peptide 1, which has been shown to modulate
LDL uptake and degradation in HepG2 cells about 15 years
ago,7 without any further veriﬁcation of a direct interaction with
HMGCoAR either in vitro or in silico. Our modeling study
shows that the interaction of this peptide with HMGCoAR is
partially impaired by its excessive length, whereas the
interaction with the shorter peptide 2 encrypted in peptide 1
is much more favorable. Thus, it seems possible to hypothesize
that peptide 2 may be the active part of peptide 1.
The computational study emphasizes that a suitable
HMGCoAR inhibitor should combine a negatively charged
portion (residues DNDEN in peptide 2) that mimics the
HMGCoAR substrate with a more hydrophobic portion
(residues YVVNP in peptide 2). It is useful to underline that
a similar situation is also observed in statins but with some
diﬀerences because the statin apolar moieties mimic the
pantothenic acid of coenzyme A, whereas the hydrophobic
regions of these soy peptides appear to be inserted in the
cofactor binding cavity.20,21
The in vitro experiments aimed at assessing whether peptides
2 and 3 are direct inhibitors of HMGCoAR have demonstrated
for the ﬁrst time that indeed these peptides, deriving either
from the α or α′ subunits of β-conglycinin, are able to act as
competitive inhibitors of HMGCoAR with a statin-like
behavior, in agreement with the in silico investigation.
The studies carried out on human hepatic cells have shown
that either peptide 2 or 3 is able to modulate cholesterol
metabolism. In particular, the functional results suggest that the
improved capability of HepG2 cells to uptake the LDL is
strictly correlated with the molecular increase of the intra-
cellular LDLR protein levels induced by these peptides upon
inhibition of the HMGCoAR activity. The outcomes of these
experimentations, i.e., increase of LDLR protein levels through
activation of SREBP2 and enhanced cell capacity to uptake
LDL cholesterol, appear to be perfectly in line with the
behavior of three soy glycinin peptides, i.e., IAVPGEVA,
IAVPTGVA, and LPYP, recently investigated by us.19 In
practice, we have demonstrated that the hypocholesterolemic
eﬀects can be exerted by peptides deriving from hydrolysis of
either β-conglycinin and glycinin, in contrast to what has been
indicated in the past.11
To our knowledge, this is the ﬁrst work showing the
molecular mechanism through which two conglycinin peptides
modulate the cholesterol pathway in HepG2 cells. It may
indicate how these bioavailable peptides function in cholesterol
homeostasis in the liver.
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